Join
Live feed
·
PRReleasevia Quantisnow
REGENXBIO Inc. logo

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

ByQuantisnow·Wall Street's wire, on your screen.
RGNX· REGENXBIO Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RGNX (REGENXBIO Inc.) and more on Quantisnow.